Genetically determined higher levels of circulating IL-2rα are suggestively positively associated with MPN risk [odds ratio (OR): 1.365,95% confidence interval (CI): 1.029–1.814, P = 0.032]. The gene discussed is IL2RA; the disease is myeloproliferative neoplasm.